Georgia Research Alliance

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company based in Atlanta, Georgia, founded in 2007. The company specializes in the discovery and development of novel therapeutics aimed at treating inflammatory diseases, including cystic fibrosis and moderately severe acne. Its lead product, CTX-4430, is a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells. Celtaxsys also focuses on manipulating immune cell migration and activation to develop treatments for cancer, inflammatory conditions, and autoimmune diseases. Through its innovative approach, the company aims to provide effective therapies for patients suffering from rare and serious inflammatory disorders.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

Urjanet, Inc. is a company that specializes in providing a cloud-based platform for automated access to utility data. Founded in 2009 and headquartered in Atlanta, Georgia, with an additional location in Chennai, India, Urjanet connects directly to utility providers to acquire and normalize utility bills and interval data. Its offerings include automated access to utility bill data across various utilities, granular measurements of energy consumption, and advanced metering infrastructure data without requiring additional hardware or software. The platform also features capabilities for weather data analysis and alerts for billing and consumption anomalies. Urjanet's solutions are designed to improve business intelligence, energy management, accounting, and procurement processes for organizations, enabling them to enhance financial performance, energy efficiency, and sustainability.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

LymphaTech, Inc. is a healthcare technology company based in Atlanta, Georgia, focused on the treatment and prevention of lymphedema. Founded in 2014, the company has developed an innovative 3D body scanning technology that enables healthcare professionals to diagnose lymphedema more effectively and promptly. The device measures limb circumference to create accurate three-dimensional models, allowing for the monitoring of geometric changes over time. This technology can be utilized both in clinical settings and at home, facilitating early detection of symptoms and enabling timely intervention. By providing an easy-to-use mobile platform powered by proprietary algorithms, LymphaTech aims to enhance the quality of life for patients, particularly breast cancer survivors, while meeting critical needs in the healthcare community.

Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular a standardized, commercialized platelet derived biologic eye drop for dry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular is an investigational drug and is not yet approved for sale in or outside the United States.

Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular a standardized, commercialized platelet derived biologic eye drop for dry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular is an investigational drug and is not yet approved for sale in or outside the United States.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia, that serves a diverse clientele, including the pharmaceutical, biotechnology, clinical, academic, and government sectors. Established in 2010, the company specializes in clinical trials, diagnostic testing, and research, with a particular focus on oncology and personalized medicine. AKESOgen offers a wide range of services, including high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping, and epigenomic analysis, all conducted to CLIA/GLP standards. Additionally, the company provides clinical and regulatory services, ensuring compliance with clinical trial protocols and molecular pathology. Its notable clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente.

Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular a standardized, commercialized platelet derived biologic eye drop for dry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular is an investigational drug and is not yet approved for sale in or outside the United States.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia, that serves a diverse clientele, including the pharmaceutical, biotechnology, clinical, academic, and government sectors. Established in 2010, the company specializes in clinical trials, diagnostic testing, and research, with a particular focus on oncology and personalized medicine. AKESOgen offers a wide range of services, including high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping, and epigenomic analysis, all conducted to CLIA/GLP standards. Additionally, the company provides clinical and regulatory services, ensuring compliance with clinical trial protocols and molecular pathology. Its notable clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia, that serves a diverse clientele, including the pharmaceutical, biotechnology, clinical, academic, and government sectors. Established in 2010, the company specializes in clinical trials, diagnostic testing, and research, with a particular focus on oncology and personalized medicine. AKESOgen offers a wide range of services, including high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping, and epigenomic analysis, all conducted to CLIA/GLP standards. Additionally, the company provides clinical and regulatory services, ensuring compliance with clinical trial protocols and molecular pathology. Its notable clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia, that serves a diverse clientele, including the pharmaceutical, biotechnology, clinical, academic, and government sectors. Established in 2010, the company specializes in clinical trials, diagnostic testing, and research, with a particular focus on oncology and personalized medicine. AKESOgen offers a wide range of services, including high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping, and epigenomic analysis, all conducted to CLIA/GLP standards. Additionally, the company provides clinical and regulatory services, ensuring compliance with clinical trial protocols and molecular pathology. Its notable clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente.

Whisper Communications is an Atlanta-based company that specializes in wireless networking services, leveraging innovative technologies to enhance data security. Utilizing patent-pending technology developed at the Georgia Institute of Technology, Whisper has created an encoding methodology that ensures data signals transmitted beyond a designated area, referred to as the "cone of silence," are rendered useless to eavesdroppers. The company's approach focuses on physical layer security, where the safety of data is intrinsically linked to its proximity to the data source. This enables IT companies to effectively monitor, track, and control devices located within a fixed area, thereby enhancing the overall security of wireless communications.